Anzeige
❌
Mehr »
Mittwoch, 06.08.2025 - Börsentäglich über 12.000 News
US-Kupfer-Geheimtipp legt nach: Strategisches Projekt zündet Phase 2 mit KI-Bohrplanung
Anzeige

Indizes
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Aktien
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Xetra-Orderbuch

Fonds
Kurs
%

Devisen
Kurs
%

Rohstoffe
Kurs
%

Themen
Kurs
%

Erweiterte Suche

WKN: A2JRKN | ISIN: KYG0520K1094 | Ticker-Symbol: 2VJ
Stuttgart
06.08.25 | 07:40
1,240 Euro
-7,46 % -0,100
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
ASCLETIS PHARMA INC Chart 1 Jahr
5-Tage-Chart
ASCLETIS PHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,2601,33020:06
1,2601,33019:50

Aktuelle News zur ASCLETIS PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiAscletis Pharma Inc.: Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Small Molecule Oral GLP-1R Agonist, ASC30, in Participants with Obesity or Overweight56PR Newswire- 13-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of two oral formulations of ASC30, a once-daily tablet, in 125 participants...
► Artikel lesen
DiASCLETIS-B (01672): VOLUNTARY ANNOUNCEMENT - ASCLETIS COMPLETES ENROLLMENT IN U.S. PHASE IIA STUDY FOR ITS SMALL MOLECULE ORAL GLP-1R AGONIST, ASC30, ...3HKEx
28.07.Ascletis Pharma Inc.: Ascletis Announces First Participants with Obesity or Overweight Dosed in Its U.S. 12-week Phase IIa Study Evaluating Once-Monthly Subcutaneous Depot Formulation of Small Molecule GLP-1R Agonist ASC3085PR Newswire- First participants with obesity or overweight with at least one weight-related comorbidity have been dosed in a U.S. 12-week Phase IIa study with once-monthly...
► Artikel lesen
28.07.ASCLETIS-B (01672): VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES FIRST PARTICIPANTS WITH OBESITY OR OVERWEIGHT DOSED IN ITS U.S. 12-WEEK PHASE IIA STUDY ...1HKEx
ASCLETIS PHARMA Aktie jetzt für 0€ handeln
21.07.ASCLETIS-B (01672): NOTICE OF BOARD MEETING2HKEx
15.07.Ascletis Pharma Inc.: Ascletis Completes Dosing of All Participants in Its U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRß Agonist, ASC47, and Semaglutide for the Treatment of ...121PR Newswire- The combination study, conducted in the U.S., is designed to evaluate the safety, tolerability and preliminary efficacy at Day 29 of a single-dose of...
► Artikel lesen
15.07.ASCLETIS-B (01672): VOLUNTARY ANNOUNCEMENT - ASCLETIS COMPLETES DOSING OF ALL PARTICIPANTS IN ITS U.S. CLINICAL STUDY COMBINING ADIPOSE-TARGETED, ONCE-MONTHLY ...3HKEx
03.07.Ascletis Pharma Inc.: Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30118PR Newswire- First participants with obesity or overweight with at least one weight-related comorbidity have been dosed in a U.S. 13-week Phase IIa study of small molecule...
► Artikel lesen
03.07.ASCLETIS-B (01672): VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES FIRST PARTICIPANTS WITH OBESITY OR OVERWEIGHT DOSED IN A U.S. 13-WEEK PHASE IIA STUDY ...6HKEx
30.06.ASCLETIS-B (01672): VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE: THIRD-PARTY PETITION FILED AGAINST THE COMPANY'S U.S. PATENT3HKEx
27.06.ASCLETIS-B (01672): NOMINATION COMMITTEE - TERMS OF REFERENCE2HKEx
18.06.Ascletis Pharma Inc.: Ascletis Announces First Participants Dosed in U.S. Phase I Clinical Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor for the Treatment of Psoriasis131PR Newswire- The Phase I trial evaluates the safety, tolerability and preliminary efficacy of ASC50 for the treatment of psoriasis.- Preclinical data, including higher oral...
► Artikel lesen
18.06.ASCLETIS-B (01672): VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES FIRST PARTICIPANTS DOSED IN U.S. PHASE I CLINICAL STUDY OF ASC50, A POTENTIAL BEST-IN-CLASS ...4HKEx
09.06.ASCLETIS-B (01672): VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES POSTER PRESENTATIONS ON THE STUDY RESULTS OF ORAL SMALL MOLECULE GLP-1R AGONIST ASC30 ...25HKEx
04.06.Ascletis's daily acne tablet set for China review after Phase III win6Pharmaceutical Technology
04.06.Ascletis says oral acne drug shows "exceptional efficacy"2pharmaphorum
04.06.Ascletis scores phase 3 win for daily acne pill, prepares push to Chinese regulators1FierceBiotech
04.06.Sagimet Biosciences Inc.: Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis168GlobeNewswire (Europe)Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to...
► Artikel lesen
04.06.Ascletis Pharma Inc.: Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints71PR NewswireDenifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated statistically significant and clinically meaningful improvement compared...
► Artikel lesen
04.06.ASCLETIS-B (01672): VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES PHASE III TRIAL OF DENIFANSTAT (ASC40), A FIRST-IN-CLASS, ONCE-DAILY ORAL FASN INHIBITOR ...3HKEx
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2